FierceBiotech names Editas Medicine as one of its “Fierce 15” Biotech Companies of 2014
Cambridge, MA – September 22, 2014 – Editas Medicine today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“It seems each year there’s a new Next Big Thing in science, but rarely are such breakthroughs quickly translated into serious therapeutic R&D efforts,” says Damian Garde, editor of FierceBiotech. “That’s where Editas stands out. As the promise of gene editing grabs headlines around the world, Editas is working to turn CRISPR technology into practical treatments, uniting leading researchers with talented management and top-tier investors.”
“We’re honored to be selected as a Fierce 15 company," said Katrine Bosley, chief executive officer, Editas Medicine. "While these are the early days of genomic medicine, we are working to unlock an entirely new category of novel therapeutic solutions for patients with genetically-driven diseases – and we are committed to broadly and expeditiously realizing that potential."
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This isFierceBiotech’s twelfth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercebiotech.com/fierce15.
An internationally recognized daily report reaching a network of over 270,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About FierceBiotech
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 270,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
About Editas Medicine
Editas is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The company was founded by the pioneers and world leaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The company’s mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases. For more information, visit www.editasmedicine.com.
###
CONTACTS:
Rebecca Friend
FierceBiotech
202-824-5050
rebecca@fiercemarkets.com
Dan Budwick
Pure Communications
973-271-6085
dan@purecommunicationinc.com
